{"id":136622,"date":"2025-05-23T08:38:50","date_gmt":"2025-05-23T08:38:50","guid":{"rendered":"https:\/\/teknomers.com\/en\/health-authorities-have-reintroduced-sanofi-in-the-race-for-the-senior-flu-vaccine\/"},"modified":"2025-05-23T08:38:52","modified_gmt":"2025-05-23T08:38:52","slug":"health-authorities-have-reintroduced-sanofi-in-the-race-for-the-senior-flu-vaccine","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/health-authorities-have-reintroduced-sanofi-in-the-race-for-the-senior-flu-vaccine\/","title":{"rendered":"Health authorities have reintroduced Sanofi in the race for the senior flu vaccine."},"content":{"rendered":"<div id=\"influenza-vaccine-update\">\n<h2>The Return of Efluelda: A Shift in French Vaccination Strategy<\/h2>\n<p>The landscape of \u00a0influenza vaccination\u00a0 in France is experiencing a significant transformation with the planned reintegration of \u00a0Efluelda\u00a0, a highly dosed flu vaccine specifically designed for seniors. This development marks a surprising turnaround in the French authorities&#8217; approach to flu vaccination, highlighting the ongoing debate surrounding the efficacy and pricing of vaccines in the country.<\/p>\n<figure class=\"article__media\">\n    <picture class=\"article__media\"><source srcset=\"https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/556\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg 556w, https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/600\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg 600w, https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/664\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg 664w, https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/700\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg 700w, https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/800\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg 800w\" sizes=\"(min-width: 1024px) 556px, 100vw\" alt=\"Highly dosed Efluelda influenza vaccine box, in a Sanofi laboratory in Val-de-Reuil (Eure), September 5, 2022.\" width=\"664\" height=\"443\"><\/source>\n    <\/picture>\n    <noscript><br \/>\n        <img decoding=\"async\" src=\"https:\/\/img.lemde.fr\/2025\/05\/23\/0\/0\/5000\/3333\/664\/0\/75\/0\/5cdf7f1_sirius-fs-upload-1-9heh4wxxchdg-1747985475875-000-32hp86t.jpg\" alt=\"Highly dosed Efluelda influenza vaccine box, in a Sanofi laboratory in Val-de-Reuil (Eure), September 5, 2022.\"\/><br \/>\n    <\/noscript><figcaption class=\"article__legend\" aria-hidden=\"true\">Highly dosed Efluelda influenza vaccine box, in a Sanofi laboratory in Val-de-Reuil (Eure), September 5, 2022.<br \/>\n        <span class=\"article__credit\" aria-hidden=\"true\">Lou Benoist \/ AFP<\/span><br \/>\n    <\/figcaption><\/figure>\n<p>This forthcoming return is the result of a \u00a0recommendation\u00a0 from the \u00a0High Authority for Health (HAS)\u00a0, issued on May 9, which endorses the usage of Efluelda among individuals aged 65 and older. The recommendation emphasizes that this vaccine should be preferred over \u00a0standard dose vaccines\u00a0 currently available. This shift represents a significant change from the authority&#8217;s previous stance in 2020, where scientific assessments deemed the benefits of Efluelda to be \u00a0\u201cmodest.\u201d\u00a0<\/p>\n<h2>Understanding Efluelda: Its Significance for Seniors<\/h2>\n<p>As we delve deeper into the implications of this decision, it is crucial to understand what Efluelda actually brings to the table. This \u00a0highly dosed vaccine\u00a0 aims to provide older adults, who are at greater risk from influenza complications, with stronger immunity. This demographic often faces higher rates of hospitalization and mortality due to the flu. By integrating Efluelda back into the vaccination options, French authorities appear to be responding to the pressing need for more effective solutions in protecting the health of senior citizens.<\/p>\n<p>Research indicates that \u00a0high-dose vaccines\u00a0 are associated with a greater immunogenic response in older populations. The body\u2019s immune response tends to weaken with age, making it imperative that seniors receive vaccines that can provide them better protection. Numerous studies have shown that high-dose influenza vaccines, like Efluelda, can lower hospitalization rates significantly compared to standard-dose vaccines.<\/p>\n<h2>Public Perception and Acceptance of Flu Vaccines<\/h2>\n<p>While the scientific benefits of Efluelda may be apparent, public acceptance and \u00a0awareness\u00a0 remain critical components of a successful vaccination strategy. Over the years, hesitance towards vaccines has been exacerbated by misinformation and fear. This has made it pivotal for health authorities to launch engaging public health campaigns that clarify the importance of influenza vaccination for the elderly and the advantages presented by vaccines like Efluelda.<\/p>\n<p>Social media platforms, community engagements, and even partnerships with healthcare providers can create a positive impact on public perception. By \u00a0educating\u00a0 communities about the safety and efficacy of Efluelda, the French health system can foster a more receptive environment for vaccination.<\/p>\n<h2>Challenges Ahead: Pricing and Distribution<\/h2>\n<p>One of the pivotal factors affecting the future of Efluelda and its role in France&#8217;s vaccination strategy is the \u00a0pricing\u00a0. During its previous market withdrawal in April 2024, disagreements arose between the French administration and its manufacturer, Sanofi, regarding the price of Efluelda. For a long-term solution, it is critical that both parties engage in fruitful negotiations that ensure the vaccine is financially accessible to all eligible individuals.<\/p>\n<p>Furthermore, the distribution channels for Efluelda will need to be carefully examined to ensure wide availability, particularly in rural sectors where access to healthcare services may be limited. Ensuring that pharmacies are adequately stocked and trained to assist seniors in understanding vaccine options will facilitate a smoother rollout.<\/p>\n<h2>Looking Forward: Optimism in Vaccination Efforts<\/h2>\n<p>The reintroduction of Efluelda represents a renewed commitment to protecting \u00a0public health\u00a0 in France, particularly among vulnerable populations. It builds upon the foundation of lessons learned during previous vaccination campaigns and offers an opportunity to adapt strategies to meet the needs of \u00a0seniors effectively\u00a0. With this renewed focus, the hope is that Efluelda will boost \u00a0vaccination rates\u00a0 and significantly reduce the impact of influenza outbreaks among older individuals in the coming seasons.<\/p>\n<\/div>\n<p><a href=\"https:\/\/teknomers.com\/en\/category\/general\/\" rel=\"dofollow\">Breaking News General &#8211; 1<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Return of Efluelda: A Shift in French Vaccination Strategy The landscape of \u00a0influenza vaccination\u00a0 in France is experiencing a significant transformation with the planned reintegration of \u00a0Efluelda\u00a0, a highly dosed flu vaccine specifically designed for seniors. This development marks a surprising turnaround in the French authorities&#8217; approach to flu vaccination, highlighting the ongoing debate [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":136623,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[37,2305,112,1315,35727,23324,1030,1325],"class_list":["post-136622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","tag-authorities","tag-flu","tag-health","tag-race","tag-reintroduced","tag-sanofi","tag-senior","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/136622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=136622"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/136622\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/136623"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=136622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=136622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=136622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}